Beam Therapeutics Reaches Analyst Target Price
October 16, 2020 at 09:24 AM EDT
In recent trading, shares of Beam Therapeutics Inc (BEAM) have crossed above the average analyst 12-month target price of $31.75, changing hands for $32.92/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..